All News

Found 387 articles

• 

  Highlighting Innovation in Breast and Ovarian Cancer on International Women's Day

  3/8/2022

  Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.

• Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

  2/17/2022

  Edesa Biotech, Inc. today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.

• IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

  2/17/2022

  IMV Inc. today announced that it is hosting a Research and Development Day” via webcast on Thursday, February 24, 2022 at 8:00am Eastern Time to highlight the differentiating features of its patented DPX delivery platform.

• Livestock Pregnancy Testing Devices Market Growth Opportunities – Forecast (2018-2028)

  1/23/2022

  Need to confirm a pregnancy is crucial in animal breeding. It is important to know which ones are getting pregnant and which ones are not in order to determine what the next steps could be.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

  1/13/2022

  Edesa Biotech, Inc. today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study.

• IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

  1/12/2022

  IMV Inc. today announced a first patient dosed in the VITALIZE Phase 2B clinical trial. VITALIZE will further evaluate the clinical benefit of IMV’s lead compound, maveropepimut-S (MVP-S).

• IMV Inc. to Present at Two Upcoming Investor Events

  1/5/2022

  IMV Inc. announced that members of IMV’s executive management team will be presenting virtually at the Biotech ShowcaseTM 2022 investor conference which will be held January 10-12 and at the H.C. Wainwright Bioconnect 2022 conference held January 10-13.

• Varian and Siemens Healthineers Recognized in Survey of U.S. Radiation Oncology and Diagnostic Imaging Professionals

  1/5/2022

  Varian and parent company Siemens Healthineers have been recognized in the annual IMV ServiceTrak™ report on industry leaders in diagnostic imaging equipment in the United States.

• Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels

  1/3/2022

  Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that a manuscript detailing the results of an analysis of CRP levels from the LIVE-AIR Phase 3 study is available on medRxiv .

• IMV Appoints Andrew Hall as Chief Executive Officer

  12/22/2021

  IMV Inc. announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022.

• IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

  12/21/2021

  IMV Inc. today announced the finalization of the basket clinical study evaluating maveropepimut-S.

• CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

  12/21/2021

  CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that it has received a positive response from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 3, randomized, double blind, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for Invasive Mechanical Ventilation ("IMV”) or Extracorporeal Membrane Oxygenation (“ECMO”).

• IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

  12/20/2021

  IMV Inc. today announced the completion of a US$25 million long-term debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon").

• CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population

  12/9/2021

  CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that it has submitted a Phase 3, randomized, double blind, placebo controlled trial with the U.S. Food and Drug Administration (“FDA”) to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for invasive mechanical ventilation ("IMV”) or Extracorporeal Membrane Oxygenation (“ECMO”).

• Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

  12/2/2021

  IMV Inc. today announced new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients.

• The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

  12/1/2021

  Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients.

• IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

  11/30/2021

  IMV Inc. today announced that the first patient with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer has been dosed with its lead compound, maveropepimut-S (MVP-S, formerly known as DPX-Survivac).

• IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

  11/23/2021

  IMV Inc. today announced that IMV’s executive management team will be participating in the upcoming Piper Sandler Virtual Healthcare Conference.

• IMV Inc. Announces Chief Financial Officer to Retire

  11/22/2021

  IMV Inc. today announced that Pierre Labbé, the Company’s Chief Financial Officer, will retire on March 31, 2022.